Brief: Medicure Announces Completion Of Enrollment For Fabolus-Faster, Phase 4 Clinical Trial Of Aggrastat Injection vs. Kengreal
12/12/2019 23:34
Dec 12 (Reuters) - Medicure Inc MPH.V :
* MEDICURE ANNOUNCES COMPLETION OF ENROLLMENT FOR
FABOLUS-FASTER,
PHASE 4 CLINICAL TRIAL OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
INJECTION VERSUS KENGREAL (CANGRELOR) IN PATIENTS UNDERGOING
PERCUTANEOUS CORONARY INTERVENTION (PCI)
* MEDICURE INC - EXPECTS TO RELEASE TOP-LINE DATA OF
FABOLUS-FASTER PHASE 4 TRIAL IN Q1 OF 2020
Source text for Eikon: ID:nCNWcGcqqa
Further company coverage: MPH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicure
See all newsBrief: Medicure Announces Resignation Of Board Member And Grant Of Stock Options
Brief: Medicure Posts Qtrly Earnings Per Share $0.11
Brief: Medicure Reports Financial Results For Quarter Ended June 30, 2022
Brief: Medicure Announces Resignation Of CFO And Succession Plan
Brief: Algernon Pharmaceuticals Appoints James Kinley As CFO Effective From December 1, 2021